These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 27998711)

  • 1. Progress and promise of antisense oligonucleotide therapeutics for central nervous system diseases.
    Bishop KM
    Neuropharmacology; 2017 Jul; 120():56-62. PubMed ID: 27998711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel therapeutic modalities to address nondrugable protein interaction targets.
    De Souza EB; Cload ST; Pendergrast PS; Sah DW
    Neuropsychopharmacology; 2009 Jan; 34(1):142-58. PubMed ID: 18754007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential of antisense as a CNS therapeutic.
    Godfray J; Estibeiro P
    Expert Opin Ther Targets; 2003 Jun; 7(3):363-76. PubMed ID: 12783572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Society for Neuroscience--38th Annual Meeting--Data for therapeutics for CNS diseases and disorders.
    Macauley D; Al-Shamahi A
    IDrugs; 2009 Jan; 12(1):17-9. PubMed ID: 19127499
    [No Abstract]   [Full Text] [Related]  

  • 5. Opportunities in systems biology to discover mechanisms and repurpose drugs for CNS diseases.
    Mei H; Xia T; Feng G; Zhu J; Lin SM; Qiu Y
    Drug Discov Today; 2012 Nov; 17(21-22):1208-16. PubMed ID: 22750722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sphingosine-1-phosphate receptor therapies: Advances in clinical trials for CNS-related diseases.
    O'Sullivan S; Dev KK
    Neuropharmacology; 2017 Feb; 113(Pt B):597-607. PubMed ID: 27825807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The need for new approaches in CNS drug discovery: Why drugs have failed, and what can be done to improve outcomes.
    Gribkoff VK; Kaczmarek LK
    Neuropharmacology; 2017 Jul; 120():11-19. PubMed ID: 26979921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Applications of imaging biomarkers in the early clinical development of central nervous system therapeutic agents.
    Cole PE; Schwarz AJ; Schmidt ME
    Clin Pharmacol Ther; 2012 Feb; 91(2):315-20. PubMed ID: 22218072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noninvasive and targeted delivery of therapeutics to the brain using focused ultrasound.
    Poon C; McMahon D; Hynynen K
    Neuropharmacology; 2017 Jul; 120():20-37. PubMed ID: 26907805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendrimer advances for the central nervous system delivery of therapeutics.
    Xu L; Zhang H; Wu Y
    ACS Chem Neurosci; 2014 Jan; 5(1):2-13. PubMed ID: 24274162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery.
    Banks WA
    Nat Rev Drug Discov; 2016 Apr; 15(4):275-92. PubMed ID: 26794270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single-cell map of antisense oligonucleotide activity in the brain.
    Mortberg MA; Gentile JE; Nadaf NM; Vanderburg C; Simmons S; Dubinsky D; Slamin A; Maldonado S; Petersen CL; Jones N; Kordasiewicz HB; Zhao HT; Vallabh SM; Minikel EV
    Nucleic Acids Res; 2023 Aug; 51(14):7109-7124. PubMed ID: 37188501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration.
    Monine M; Norris D; Wang Y; Nestorov I
    J Pharmacokinet Pharmacodyn; 2021 Oct; 48(5):639-654. PubMed ID: 33991294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thiazole: a promising heterocycle for the development of potent CNS active agents.
    Mishra CB; Kumari S; Tiwari M
    Eur J Med Chem; 2015 Mar; 92():1-34. PubMed ID: 25544146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trials in CNS--SMi's eighth annual conference.
    Kirk R
    IDrugs; 2010 Feb; 13(2):66-9. PubMed ID: 20127552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinase inhibitors for CNS diseases: an analysis of the recent patent literature.
    Amigoni F; Legnaghi E; Pevarello P
    Pharm Pat Anal; 2012 May; 1(2):177-92. PubMed ID: 24236782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxicology of antisense therapeutics.
    Jason TL; Koropatnick J; Berg RW
    Toxicol Appl Pharmacol; 2004 Nov; 201(1):66-83. PubMed ID: 15519609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The therapeutic potential of sigma (σ) receptors for the treatment of central nervous system diseases: evaluation of the evidence.
    Banister SD; Kassiou M
    Curr Pharm Des; 2012; 18(7):884-901. PubMed ID: 22288410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense oligonucleotides for target validation in the CNS.
    Ho SP; Hartig PR
    Curr Opin Mol Ther; 1999 Jun; 1(3):336-43. PubMed ID: 11713799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges in the search for drugs to treat central nervous system disorders.
    Enna SJ; Williams M
    J Pharmacol Exp Ther; 2009 May; 329(2):404-11. PubMed ID: 19182069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.